Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy

Abstract

Interferon beta-1a is an established therapy for patients with relapsing-remitting multiple sclerosis (MS). Adverse effects in the first weeks of treatment are common. This open-label, multicenter, randomized, prospective study compared treatment of flu-like symptoms (FLS) with paracetamol versus ibuprofen administered 48 h within interferon injection. The percentage of patients with FLS was comparable between both treatment groups and improved during the course of the study (baseline: paracetamol 92%, ibuprofen 90%; week 12: paracetamol 60%, ibuprofen 57%). More than 75% of patients receiving either paracetamol or ibuprofen reported no or only mild impairment of daily activities. There was no significant difference in general satisfaction or incidence of additional symptoms (weakness, nausea, headache; paracetamol 84.6% patients, ibuprofen 86.0% patients) between the two groups. A significant overall improvement from baseline to week 12 was observed for all parameters studied (paracetamol and ibuprofen groups were pooled). These results indicate that neither the paracetamol nor the ibuprofen treatment regimen is better.

Keywords

adverse events antipyretics human interferon interferon beta-1a multiple sclerosis side effects

References

Jacobs LD , Cookfair DL , Rudick RA , et al. Intramuscular inter-feron beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

Walther EU , Hohlfeld R. Multiple sclerosis: side effects of inter-feron beta therapy and their management . Neurology 1999; 53: 1622-1627 .

Herndon RM , Jacobs LD , Coats ME , et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis . Int J MS Care 1999; 1: 1-6 .

Munschauer FE , Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis . Clin Ther 1997; 19: 883-893 .

Lublin FD , Whitaker JN , Eidelman BH , et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference . Neurology 1996; 46: 12-18 .

Bayas A , Rieckmann P. Managing the adverse effects of interferon-b therapy in multiple sclerosis . Drug Saf 2000; 22: 149-159 .

Rice GPA , Ebers GC , Lublin FD , Knobler RL. Ibuprofen treatment versus gradual introduction of interferon b-1b in patients with MS . Neurology 1999; 52: 1893-1895 .

Mohr DC , et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a . Mult Scler 1998; 4: 487-489 .

Rieckmann P , et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis . J Neuroimmunol 1996; 64: 193-200 .

10.

Weber F , et al. Synergistic immunomodulatory effects of inter-feron-b-1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis . Ann Neurol 1998; 44: 27-34 .

11.

Róo J , et al. Low-dose steroids reduce flu-like symptoms at the initiation of IFNb-1b in relapsing-remitting MS . Neurology 1998; 50: 1910-1912 .

12.

Sellebjerg F , Fredriksen MD , Nielsen PM , Olsen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS . Neurology 1998; 51: 529-534 .